ST HELIER, JERSEY / ACCESS Newswire / August 17, 2026 / Caledonia Mining Corporation Plc ("Caledonia" or "the Company") announces that it received notification on August 14, 2026 that Mr July Ndlovu, a Non-Executive Director and Chairman of Caledonia, had purchased 21,400 common shares in the Company on August 13, 2026 at a price of $23.03 per share (the "Purchase").

Following the Purchase, Mr Ndlovu now has an interest in 250,489 common shares in the Company.

A copy of the notification is below.

Enquiries:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

SOURCE: Caledonia Mining Corporation Plc

1H-2026 Net Revenues Reached Record $3.7 million, up 94%, with Adj. EBITDA at $254,000 
 

LAS VEGAS, NV / ACCESS Newswire / August 14, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical formulations and precision dose gummy manufacturing, reported another period of record revenues and adj. EBTIDA for the second quarter and first half ended June 30, 2026. All financial comparisons are to the same year-ago period unless otherwise noted.

Q2 2026 Financial Highlights

• Net revenue increased 113% to record $2.1 million, with strong topline performance largely due to the synergistic merger with Gummy USA™ in October 2025 and acquisition of Imaraïs Beauty in May of this year. Both added new product lines and B2B customers and expanded the company's distribution channels.

• Gross profit increased 145% to $1.5 million, with gross margins increasing from 61.2% to 70.3%.

• Net loss totaled $129,000 or ($0.01) per basic and diluted share, compared to net income of $67,000 or $0.02 per basic and diluted share in the same year-ago quarter.

• EBITDA increased 75% to $169,000, with adj. EBITDA totaling $290,000 or $0.02 per basic and diluted share (see definitions of these non-GAAP terms and their reconciliation to GAAP in the section, Use of Non-GAAP Measures, below).

Q2 2026 Operational Highlights

• In April, Healthy Extracts' wholly owned subsidiary, Gummy USA, entered a U.S. manufacturing partnership with Imaraïs Beauty, the popular plant-based ingestible beauty and wellness brand founded by media personality, Sommer Ray, and award-winning supplement industry veteran, Aaron Hefter. Imaraïs has broad distribution across major U.S. retail channels, including Target, Ulta Beauty and Sprouts, as well as numerous international outlets.

• Imarais Beauty partnership launched with an initial large order totaling nearly 4 million gummies across five existing SKUs. The order has begun shipping to more than 4,000 store locations nationwide that include highly visible isle end-cap placements.

• In May, the new partnership with Imarais Beauty transformed into its acquisition by Healthy Extracts, resulting in Imarais Beauty becoming a new wholly owned operating subsidiary. Since its founding in 2020, Imaraïs Beauty has attracted worldwide acclaim and countless loyal customers and social media influencers, with the brand sold worldwide through thousands of retailer locations and online. Imaraïs Beauty's phenomenal success has been featured in major business publications, including WWD, Forbes, Beauty Independent, and Entrepreneur.

• Healthy Extracts' transformative strategic merger with Gummy USA last fall has continued to address the large unmet need in the nutraceutical and pharmaceutical industry for precision-dosed gummy manufacturing technology, with this opening the door to new specialized B2B product development.

Management Commentary

"Our second quarter of 2026 represented another great quarter of record-setting revenues and market expansion," stated Healthy Extracts CEO, Don Swanson. "As our ninth consecutive quarter of year-over-year revenue growth, our momentum has continued to build.

"Our strong topline performance reflects the continued evolution of our company into an industry leader in nutraceutical innovation. The integration of Gummy USA and Imarais Beauty has accelerated our growth and expanded our product lines and addressable markets. They have also brought to us new major retailer customers from around the world. This has resulted in a significant increase in B2B, direct-to-consumer and retail sales.

"We have continued to focus on our long-term strategic growth strategies, with this including the achievement of superior leadership in formulation and manufacturing technologies that target the high-growth, high-margin Nutra Pharma and Health & Beauty sectors.

"We are enjoying vast new opportunities where we can leverage our strengths in advanced formulations, manufacturing, and proprietary oral delivery technologies. We expect these efforts to benefit from the strong industry growth in our health and beauty category that is expected to top $730 billion this year. We also see many great opportunities in the broader health and wellness markets.

"Our new manufacturing partnership with Imaraïs Beauty quickly evolved into their acquisition due to the many strong synergies between our two companies. Their advanced formulations are unlike anything I've seen in the gummy market today, while our precision dosing technology aligns perfectly with their commitment to premium quality, innovation, and rapid global market expansion.

"We expect Imaraïs' market reach and retail momentum to accelerate our in-house gummy manufacturing output for the remainder of the year. To be sure, this is not only for the beauty and wellness category, but also as we continue to deliver the next generation of functional and OTC gummy delivery systems across multiple categories within our large consumer health market.

"We see our strong results for the second quarter as just the beginning of a highly scalable, transformational growth phase for Healthy Extracts. By leveraging our advanced U.S. manufacturing capabilities, we believe we have a tremendous opportunity to expand our brand presence worldwide.

"Given our many commercial initiatives, which includes new B2B customer engagement and product development, we continue to believe we have the potential to achieve annualized net revenue of more than $20 million by year end or up 3x over last year. While this aspirational goal is aggressive, we believe it is supported by our current sales pipeline and existing manufacturing and distribution capacity.

"We see the key to achieving our goals will be our unique precision dose manufacturing capabilities and exclusive licensed delivery systems. We believe these two factors provide exceptional differentiation within our Nutraceutical, Nutra Pharma and Functional Wellness markets, and they have set the stage for an exceptionally strong period ahead.

"Gummy USA and Imaraïs Beauty have joined us during a period of increased investor interest and consolidation within the gummy and wellness sector. Many high-profile industry deals, such as the recent $1.2 billion acquisition of Grüns Gummies by Unilever, highlight the market demand for scalable wellness brands, and especially those that possess strong consumer engagement, differentiated product positioning, and growing retail distribution.

"As we look to the second half of the year and beyond, our mission is clear: build one of the most trusted, innovative, and respected health, wellness and beauty companies in the world, while delivering sustainable long-term value to our stakeholders. We welcome you to join us on this exciting journey."

Q1 2026 Financial Summary

Net revenue increased 113% to record $2.1 million from $969,000 in the second quarter of 2025. The increase was largely due to the synergistic merger with Gummy USA™ in October 2025 and the acquisition of Imaraïs Beauty in May of this year which added new product lines and B2B customers and expanded the company's distribution channels. The company expects net revenue growth to increase as its direct consumer sales and marketing efforts continue to perform.

Gross profit increased 145% to $1.5 million or 70.3% of net revenue, compared to $593,000 or 61.2% of net revenue in the same year-ago quarter. The increase in gross profit was due to greater sales and higher margins enabled by the merger with Gummy USA and acquisition of Imaraïs Beauty.

Operating expenses increased 115% to $1.5 million compared to $699,000 in the same year-ago quarter. The increase was due in part to additional salaries and wages associated with the addition of Gummy USA and Imaraïs Beauty as well as an increase in stock-based compensation expense.

Net loss totaled $129,000 or ($0.01) per basic and diluted share, compared to net income of $67,000 or $0.02 per basic and diluted share in the same year-ago quarter. The increase in net loss was largely due to increased interest expense, change in the fair value of derivatives, and increased G&A expense related to the addition of Gummy USA and Imaraïs Beauty.

EBITDA increased 75% to $169,000 from $97,000 in the same year-ago quarter.

Adjusted EBITDA, which adjusts additionally for non-cash stock-based expense and change in fair value of derivatives, totaled $290,000 or $0.02 per basic and diluted share, compared to an adjusted EBITDA loss of $25,000 or ($0.01) per basic and diluted share in the same year-ago quarter.

Cash totaled $190,000 at June 30, 2026, up from $147,000 at December 31, 2025, with the increase primarily due to cash generated by operations and financings.

About Healthy Extracts "Live Life Young Again"

Healthy Extracts Inc. (OTCQB:HYEX) is a leader in nutraceutical innovation, precision-dose oral delivery systems, and functional wellness consumer brands. The company develops, manufactures, and markets science-based products focused on beauty, wellness, brain, heart, gut, and lifestyle health through proprietary formulations, advanced delivery technologies, and scalable national retail distribution.

Through its acquisition of Imaraïs Beauty, the celebrity-founded ingestible beauty and wellness brand co-founded by Sommer Ray and entrepreneur Aaron Hefter, Healthy Extracts has significantly expanded its position within the rapidly growing global beauty and personal care market. Imaraïs Beauty combines advanced functional beauty formulations with strong consumer engagement, influencer-driven branding, and expanding global retail distribution across major retail, including Target, Ulta Beauty, Nordstrom, and Sprouts, and international markets.

Healthy Extracts' wholly owned subsidiary, Gummy USA™, is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Proprietary, patent-pending SureDose™ technology is designed to deliver superior dosing accuracy, safety, efficacy, and consumer compliance for both company-owned and partner brands.

The company's portfolio also includes BergametNA™ and Ultimate Brain Nutrients™ (UBN™) which offer science-backed supplements supporting cardiovascular and cognitive health. Healthy Extracts additionally maintains exclusive agreements for innovative oral delivery technologies, including Gelteq gel delivery systems and the Gut Health Straw platform, which are designed to improve bioavailability and consumer convenience.

To learn more, visit Healthy Extracts Inc., Imaraïs Beauty, BergametNA, Ultimate Brain Nutrients, or Gummy USA.

Use of Non-GAAP Measures

This press release contains financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which may include EBITDA, adjusted EBITDA and non-GAAP net income as defined below for the purpose of this press release.

EBITDA is defined as net income before income tax expense, interest expense (net of interest income), depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to stock-based option/warrant expense, stock issued for services, change in fair value of derivative, offering costs, and M&A-related expense. Non-GAAP net income excludes interest expense (net of interest income), depreciation, amortization and stock-based expenses (stock-based option/warrant expense and stock issued for services), and M&A-related expense.

Healthy Extracts' management believes that EBITDA, adjusted EBITDA, and non-GAAP net income are useful supplemental measures of the company's operating performance and can provide investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA and non-GAAP net income are also presented because management believes that it provides investors additional measures of the company's core business. However, such non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that such non-GAAP measures should not be construed as an alternative to net income or loss or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management's method of calculating EBITDA, adjusted EBITDA, and non-GAAP net income may differ materially from the method used by other companies and accordingly may not be comparable to similarly titled measures used by other companies.

A reconciliation of EBITDA and adjusted EBITDA to net income, the most comparable GAAP measure, is included in the table below. The calculation of non-GAAP net income is derived from the amounts presented in this table. For the weighted average number of common shares used for the determination of adjusted EBITDA and non-GAAP income basic and diluted earnings per common share, see the table, Consolidated Statement of Operations, further below.

Safe Harbor Notice and Important Cautions Regarding Forward-Looking Statements

The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its full second quarter results and files it Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 8, 2026, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Food & Drug Administration Disclosure

The products and formulations featured in this release are not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Gummy USA ™, BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are trademarks and registered trademarks of Healthy Extracts™ Inc.

Company Contact

Don Swanson, CEO
Healthy Extracts Inc.
Tel (801) 232-0753
Email contact

Investor Contact
CMA Investor Relations
Tel (949) 432-7554
https://www.capitalmarketaccess.com/contact

HEALTHY EXTRACTS INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDING JUNE 30, 2026 AND 2025
(UNAUDITED)

The accompanying notes are an integral part of these unaudited consolidated financial statements

HEALTHY EXTRACTS INC.
CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2026 AND DECEMBER 31, 2025
(UNAUDITED)

SOURCE: HEALTHY EXTRACTS INC.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

SOURCE: Revive Therapeutics Ltd.

Under the engagement, Humbercrest will introduce Gemdale to a targeted group of Canadian capital markets participants and coordinate a roadshow for Gemdale, with the objective of broadening investor awareness, developing relationships with prospective investors and supporting the Company's capital markets activities in advance of potential future financings. The Company expects that the services to be provided under the Agreement will be complete on or about September 14, 2026.

Pursuant to the Agreement, the program is expected to cost approximately C$13,500 in aggregate, plus applicable taxes and expenses. The Company paid 50% of the C$13,500 fee to Humbercrest upon execution of the Agreement. The remaining 50% of the C$13,500 fee is payable upon completion of the roadshow to be coordinated pursuant to the Agreement. All fees will be paid out of the Company's working capital.

None of Humbercrest or any of its principals has any interest, directly or indirectly, in Gemdale or its securities, nor any right or intent to acquire such an interest. None of Gemdale's compensation of

Humbercrest for services to be provided is contingent or conditional on changes in the Company's share price or other performance metrics and Humbercrest will not receive any securities as compensation.

The Agreement remains subject to the acceptance of the TSX Venture Exchange.

About Humbercrest

Humbercrest (address: 103 - 47 Macaulay Ave, Toronto, ON M6P 3P5) is a Toronto-based advisory providing investor relations, strategic communications and investor access for public companies, of which Michael Joyner is founder and principal. Drawing on more than 20 years of capital markets experience, Humbercrest works closely with management teams to broaden investor awareness, build lasting relationships with the investment community and support long-term shareholder value.

About Gemdale Gold

Gemdale Gold Inc. owns a portfolio of highly prospective exploration licenses in Finland and is focused on making significant new gold and critical metal discoveries on these properties. The Company has been active in Finland since 2018. The Company's 100% owned projects include:

Pontio Gold Project (western-central Finland): Historical and recent drilling has outlined near-surface gold mineralisation along a multi-kilometre trend that remains open along strike and at depth. The Company started an infill and extension drill program in February 2026, and, based on this program, plans to deliver a maiden mineral resource estimate in early 2027.

Isoneva (western-central Finland): Exploration stage gold project located proximal to extensive boulder train anomalies. The property is subject to an option agreement (the "Isoneva Option") with Nordique Resources Inc. ("Nordique") pursuant to which Nordique may earn a 100% interest by, among other things, funding exploration expenditures over a three-year period and making additional financial commitments to the Company. For more information on the Isoneva Option, please see the Company's final long form prospectus dated January 30, 2026, under the heading "Business of the Corporation - January 1, 2025, to the date hereof".

Lapland Projects (northern Finland): A group of exploration permits and applications located within a recognized gold and base-metal exploration region, in proximity to several recent regional discoveries, including Rupert Resources' Ikkari gold project.

Nuotti (western-central Finland): Copper-nickel-platinum-palladium exploration license where limited historical government drilling indicates the presence of near-surface copper-PGM mineralisation.

Savo / Rantasalmi (southeastern Finland): Exploration license application area containing a historical NI 43-101 Inferred resource estimate prepared by a prior operator of 3.23 million tonnes grading 2.7 g/t gold for approximately 276,000 ounces of gold.

Bearing an effective date of November 9, 2018, Rupert Resources Ltd. filed on SEDAR a Mineral Resource Estimate completed by Brian Wolfe (Qualified Person) of International Resource Solution Pty Ltd. and titled "NI 43-101 Technical Report: Osikönmaki Gold project, Finland". No new data subsequent to an earlier 2011 estimate was included in this study. This study used Multiple Indicator Kriging (MIK) for the estimation of grade into the block model. This study assumed a combined open pit and underground mining operation, recoveries of 85-90% and a gold price of EUR 1,200/oz (current gold price ~ EUR 4240/oz). The use of MIK as an estimation method, along with the requirements of a greater degree of confidence in the geological continuity for underground mining, were given as the reasons for the assigned lower resource category of Inferred Resources compared to the prior resource estimate in 2011. The Resource Estimate was reported at a cut-off grade of 1.5 g/t Au.

The Company is not aware of any further drilling or sampling being conducted on the property since this historical estimate was completed. Gemdale Gold Inc is not treating this historical estimate as a current resource estimate. Neither Gemdale Gold Inc nor a Qualified Person has done sufficient work to classify the historical estimate as a current Mineral Resource Estimate. The Company believes this historical estimate is relevant and reliable in providing insight into the potential mineral resources for the project based on historical drilling completed to date. Gemdale believes that further drilling is not required, but that it is necessary for a Qualified Person to review the assumptions and methodology used for the estimation, to verify or upgrade these historical resources to a current Mineral Resource Estimate.

Additional disclosure, including the Company's financial statements, technical reports, news releases and other information, can be obtained at https://gemdalegold.com/ or on SEDAR+ at https://www.sedarplus.ca/home/#.

ON BEHALF OF GEMDALE GOLD INC

"Dr. Toby Strauss"
President & CEO

For Further Information Please Contact:

Website: www.gemdalegold.com

Cautionary Note on Forward-Looking Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking information"). Forward-looking information includes, but is not limited to, statements regarding the Company's exploration and development plans, in particular the ongoing drill program on the Pontio Gold Project, other anticipated drill programs, potential mineralisation, resource estimates, future financing plans, use of proceeds, regulatory approvals, including the approval of the TSX Venture Exchange of the Agreement, market conditions and the Company's future business objectives. Forward-looking information is generally identified by the use of words such as "plans," "expects," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates," "believes," or variations of such words and phrases, or statements that certain actions, events or results "may," "could," "would," "might" or "will" occur or be achieved.

Forward-looking information is based on a number of assumptions that management believes to be reasonable at the time such statements are made, including, without limitation, assumptions regarding the availability of capital, the receipt of required regulatory approvals, the continuation of favourable market conditions, the accuracy of historical and technical data, and the Company's ability to execute its exploration and development plans as currently contemplated. However, forward looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Such factors include, without limitation, risks related to exploration and development activities, commodity price fluctuations, availability of financing, regulatory approvals, including any failure to obtain the approval of the TSX Venture Exchange of the Agreement, environmental and permitting risks, operational risks, and general economic and market conditions.

Accordingly, readers should not place undue reliance on forward-looking information. Although the Company believes the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.

SOURCE: Gemdale Gold Inc.

Selected Financial Highlights for the Three Months Ended June 30, 2026:

• Total revenues were $773,977 for the quarter ended June 30, 2026, compared to $937,774 for the quarter ended June 30, 2025, representing a decrease of 17.5%.

• Operating expenses were $820,213 for the quarter ended June 30, 2026, compared to $665,586 for the quarter ended June 30, 2025, representing an increase of 23.2%.

• Loss from operations was $46,236 for the quarter ended June 30, 2026, compared to income from operations of $272,188 for the quarter ended June 30, 2025, representing a decrease of 116.9%.

• Net income was $73,787, or $0.01 per fully diluted share, for the quarter ended June 30, 2026, compared to $26,326, or $0.00 per fully diluted share, for the quarter ended June 30, 2025, representing an increase of 180.3%.

Selected Financial Highlights for the Six Months Ended June 30, 2026:

• Total revenues were $1,946,413 for the six months ended June 30, 2026, compared to $1,912,326 for the six months ended June 30, 2025, representing an increase of 1.8%.

• Operating expenses were $1,866,081 for the six months ended June 30, 2026, compared to $1,211,367 for the six months ended June 30, 2025, representing an increase of 54.1%.

• Income from operations was $80,332 for the six months ended June 30, 2026, compared to $700,959 for the six months ended June 30, 2025, representing a decrease of 88.5%.

• Net income was $19,127, or $0.00 per fully diluted share, for the six months ended June 30, 2026, compared to $172,184, or $0.01 per fully diluted share, for the six months ended June 30, 2025, representing a decrease of 88.9%.

• Cash provided by operating activities was $1,041,428 for the six months ended June 30, 2026.

• The Company had cash on hand of $2,446,418 as of June 30, 2026, compared to cash on hand of $837,767 as of December 31, 2025.

About Zoned Properties, Inc. (OTCQB:ZDPY):

Zoned Properties Inc. ("Zoned Properties" or the "Company") (OTCQB:ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States.

Headquartered in Scottsdale, Arizona, Zoned Properties has developed a national ecosystem of real estate services to support its real estate development model, including a commercial real estate brokerage and a real estate advisory practice. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties addresses the specific needs of a modern market in highly regulated industries. The Company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value, and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substance Act of 1970, as amended. For more information, call 877-360-8839 or visit www.ZonedProperties.com.

X: @ZonedProperties
LinkedIn: @ZonedProperties

Safe Harbor Statement

This press release contains forward-looking statements. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company's filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Relations

Zoned Properties, Inc.
Bryan McLaren
Tel (877) 360-8839
Investors@zonedproperties.com
www.zonedproperties.com

SOURCE: Zoned Properties, Inc.

BLX CN will be removed, and its weight distributed pro rata to remaining Index constituents.

About Tortoise Capital
With approximately $11.1 billion in assets under management as of July 31, 2026, Tortoise Capital's solid record of investment experience and research dates back more than 20 years. As one of the earliest investors in midstream energy, Tortoise Capital believes it is well-positioned to be at the forefront of the global energy evolution that is under way. For more information about Tortoise Capital, visit www.TortoiseCapital.com.

The Tortoise Decarbonization Infrastructure IndexSM is a float-adjusted, capitalization weighted index of decarbonizing infrastructure companies that are organized and have their principal place of business in the United States or Canada. We define a decarbonization infrastructure company as a company that primarily owns natural gas and/ or natural gas liquids infrastructure including pipelines and local distribution companies, electric generation, transmission and distribution, battery storage, electric charging infrastructure, residential rooftop solar facilities and/ or renewable fuels.

The index mentioned above is the exclusive property of Tortoise Capital and is calculated by Solactive AG ("Solactive"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive AG ("Solactive") in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or the completeness of the Index or the calculations thereof; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index.

This data is provided for informational purposes only and is not intended for trading purposes. This document shall not constitute an offering of any security, product or service. The addition, removal or inclusion of a security in the index is not a recommendation to buy, sell or hold that security, nor is it investment advice. The information contained in this document is current as of the publication date. Tortoise makes no representations with respect to the accuracy or completeness of these materials and will not accept responsibility for damages, direct or indirect, resulting from an error or omission in this document. The methodology involves rebalancing and maintenance of the index that is made periodically during each year and may not, therefore, reflect real time information.

Safe Harbor Statement

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Contact information
For more information contact Eva Lipner at (913) 890-2165 or info@tortoisecapital.com.

SOURCE: Tortoise Capital

MIRAMICHI, NB / ACCESS Newswire / August 14, 2026 / SLAM Exploration Ltd. (TSXV:SXL)(OTCQB:SXLXF) ("SLAM" or the "Company") is pleased to report a 24.60 meter ("m") core interval grading 1.19% copper equivalent ("Cu-Eq") from the massive sulphide zone previously reported in hole GW26-29 (see news release dated June 17, 2026). In addition, the Company has made several new discoveries by testing VTEM plate models. These include a new discovery of massive sulphides in hole GW26-36 located 2,000 meters northwest of the Logan zone. This is a major extension of the copper-nickel cobalt potential at Goodwin. The Company has drilled 2,600 meters in 12 holes (GW26-26 through GW26-38), roughly 37% of the 2026 drilling program, and has submitted 992 core samples for multi-element assay.

Diamond Drilling Highlights - Hole GW26-29:

As previously reported, hole GW26-29 is a 100 meter step-out along strike to the southeast of hole GW25-15 on the Logan zone. Cu Eq% values are recovered grades calculated using a 95% recovery rate and metal prices for copper, nickel and cobalt published August 11, 2026 on Daily Metal Price. A total of 64 core samples were submitted for assay from GW26-29.

Drilling Update: 12 Holes Drilled

The Company has drilled 12 holes, GW26-26 through GW26-38, all designed to test VTEM plate model targets along the Logan, Granges and Farquharson trend. Testing of these VTEM targets has been very successful and has resulted in several new discoveries. All 12 holes have intersected the host gabbro with variable sulphide mineralization ranging from disseminated to massive. Samples from all 12 holes have been submitted for assay.

GW26-32 (317 m)

GW26-32 intersected a gabbro host with multiple stacked mineralized zones between 84 m and 308.7 m and several massive to semi-massive sulphide intercepts at depth including a massive sulphide interval from 287.1-287.9 m. A total of 271 samples, including QA/QC standards and blanks, were submitted for assay.

GW26-33 (233 m)

GW26-33 intersected a 14.5 meter zone of semi-massive pyrrhotite-chalcopyrite mineralization from 33.15 to 47.6 m, including massive sulphide from 33.15-35 m and a semi-massive interval from 42.6-47.1 m, hosted in gabbro. Background mineralization of 1-2% pyrrhotite continues through the remainder of the hole to 197.7 m.

GW26-36 (212 m)

GW26-36 intersected a broad mineralized zone from 124.4 to 191.8 m hosted in coarse-grained gabbro, containing several massive sulphide intervals - including 126.5-128.6 m, 140.7-142.0 m, 142.35-142.4 m, 144.5-144.7 m and 151-151.7 m together with semi-massive zones at 157-158 m and 165.4-166.3 m. A shallower semi-massive interval was also logged from 12.40-12.75 m. This new sulphide discovery is located 2,000 meters northwest of the Logan zone.

NBJMAP Grant Of $60,000

SLAM Exploration Ltd. has been awarded a grant of $60,000 by the Province Of New Brunswick in support of the 2026 diamond drilling campaign on the Goodwin copper-nickel-cobalt project. The Company wishes to thank the Province for its continued support and recognition of the strategic mineral potential at Goodwin.

Sampling and QA/QC Procedures

A total of 992 core samples have been collected from the 12 completed holes (GW26-26 through GW26-38, excluding the abandoned GW26-35) and submitted for multi-element assay. Quality control samples, comprising certified reference standards and blanks, were inserted at regular intervals in accordance with industry-standard protocols. All samples were collected, labelled and sealed by SLAM field personnel. Core is stored securely at the Company's core logging facility in Bathurst. Assay results will be reported in subsequent news releases as they are received.

About the Goodwin Project

The Goodwin copper-nickel-cobalt project covers 14,000 hectares (35,000 acres) in the mineral-rich Bathurst Mining Camp ("BMC") of New Brunswick, Canada. Background on the VTEM survey, target generation and the design of the current 7,000 meter program is set out in the Company's news releases dated June 1 and June 17, 2026. Significant historical intercepts on the property include a 64.90 meter core interval grading 2.19% Cu-Eq, including 3.84% Cu-Eq over a 31.20 meter core interval, from hole GW24-02, as reported in a news release dated August 7, 2024.

About SLAM Exploration Ltd.

SLAM Exploration Ltd. is a publicly listed resource company with a 40,000-hectare portfolio of mineral claim holdings in the mineral-rich province of New Brunswick. The portfolio is built around the Goodwin Copper Nickel Cobalt project in the Bathurst Mining Camp ("BMC") of New Brunswick. The Company also holds the Jake Lee gold project, where a new gold vein discovered in 2025 has returned up to 40.5 g/t gold and 63.30 g/t silver from channel samples, and the Menneval gold project, where a soil anomaly measuring approximately 3,000 by 2,500 meters has returned gold-bearing samples up to 0.683 g/t gold.

SLAM is a project generator and expects to receive further cash and share payments in 2026. In 2025, the Company received 1,200,000 shares plus cash from Nine Mile Metals Inc. (NINE) pursuant to the Wedge project agreement, and a cash payment of $60,000 plus 180,000 shares of a private company pursuant to the Ramsay gold agreement. The Company holds NSR royalties and expects additional cash and share payments on both the Wedge copper-zinc project and the Ramsay gold project.

To view SLAM's corporate presentation, click here. Additional information is available on SLAM's website and on SEDAR+ at www.sedarplus.ca. Follow SLAM on X @SLAMGold, and join the Company newsletter here to receive timely company updates and news releases.

Qualifying Statement

Mike Taylor, P.Geo., President and CEO of SLAM Exploration Ltd., is a qualified person as defined by National Instrument 43-101 and has approved the contents of this news release.

Contact Information

Mike Taylor, President & CEO
506-623-8960 · mike@slamexploration.com

Jimmy Gravel, Vice-President
902-273-2387 · jimmy@slamexploration.com

SEDAR+: 00012459

Forward-Looking Statements

This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances, and are often identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "may," "could," "would," "might," or "will," and similar expressions.

Forward-looking statements in this news release include, but are not limited to, statements regarding: the exploration potential of the Goodwin copper-nickel-cobalt project; the interpretation of geological, geochemical and geophysical data; the identification and prioritization of exploration targets; the anticipated receipt and significance of pending assay results; the continuity and extent of mineralized structures; the timing and scope of future exploration programs; the Company's ability to advance its mineral projects; and the potential for future exploration success.

Forward-looking statements are based on reasonable assumptions made by the Company as of the date of this news release, including that historical exploration results and publicly reported third-party mineral resources are relevant for regional and exploration context; that geological interpretations and targeting models are reasonable; that pending assay results will be received within anticipated timeframes; that planned exploration activities can be executed as expected; that contractors, equipment, personnel and supplies will be available on acceptable terms; that commodity prices and market conditions will remain generally supportive; and that required permits, approvals and access rights will be obtained in a timely manner.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied, including the speculative nature of mineral exploration; the risk that exploration results, including pending assay results, may not confirm historical data or current interpretations; uncertainty regarding the continuity, grade and extent of mineralization; delays or changes to exploration programs; availability and cost of labour, equipment and contractors; fluctuations in commodity prices; availability of financing on acceptable terms; regulatory, environmental and permitting risks; operating hazards; and general economic, market and business conditions. Additional risk factors are described in the Company's most recently filed Management's Discussion and Analysis and other continuous disclosure documents available under the Company's profile on SEDAR+.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: SLAM Exploration Ltd.

Access the interviews in their entirety at:

• PHOS: https://www.redchip.com/assets/access/phos_access

• BIVI: https://www.redchip.com/assets/access/bivi_access

John Passalacqua, Founder and CEO of First Phosphate, appears on the RedChip Small Stocks, Big Money™ show to discuss the company's progress in advancing its Bégin-Lamarche phosphate project and building a vertically integrated North American supply chain for lithium iron phosphate (LFP) batteries.

Passalacqua highlights approximately $21.5 million in non-repayable Canadian government funding secured within six months for mine concentrator development, road infrastructure and power transmission, which, together with the company's treasury, provides funding to advance the project through feasibility, permitting and toward a final investment decision. He also discusses growing government and international support for high-purity igneous phosphate as a strategic input for Western LFP battery supply chains, including interest from Canada, the United States, Europe and the G7.

Passalacqua outlines the anticipated growth in demand for LFP materials across energy storage, robotics, mobility, drones and other applications and explains how First Phosphate's mine-to-market strategy is designed to integrate its high-purity phosphate resource through purified phosphoric acid and LFP cathode active material production, supporting the onshoring of the LFP battery supply chain in North America.

Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks, Big Money™ show to discuss topline results from the Company's Phase 2 clinical trial evaluating bezisterim in Parkinson's disease.

Do highlights statistically significant improvements versus placebo across measures of motor and non-motor symptoms, as well as biomarker findings that the Company believes support bezisterim's potential impact on neuroinflammation and disease progression. He also outlines BioVie's next steps for the Parkinson's program, including continued analysis of the clinical data, preparation for an End-of-Phase 2 meeting with the FDA, planning for a potential pivotal Phase 3 registrational trial and the potential reactivation of partnering discussions.

Do also discusses the Company's fully enrolled, 200-patient long COVID trial, supported by a $13 million grant, with topline data targeted for after Labor Day. He identifies the continued advancement of bezisterim in Parkinson's disease, the upcoming long COVID data readout and potential regulatory and partnering developments as key catalysts for investors to watch.

PHOS and BIVI are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About First Phosphate Corp.

First Phosphate (NASDAQ:PHOS)(CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate's flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.

About BioVie, Inc.

BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer's and Parkinson's disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US and CNBC; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat

RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected broadcast of interviews, the future plans, objectives, expectations, strategies, products, technologies, clinical development, regulatory pathways, commercial opportunities, partnerships, revenue potential, growth prospects, and anticipated milestones or catalysts of First Phosphate Corp. and Biovie, Inc. Forward-looking statements are based on current expectations, estimates, and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the ability of each company to execute its business strategy, obtain necessary regulatory approvals, successfully develop and commercialize its products and technologies, secure and maintain strategic partnerships, obtain financing, maintain compliance with applicable listing standards, and other risks described in each company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Neither First Phosphate Corp., Biovie, Inc., nor RedChip Companies undertakes any obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release, except as required by applicable law.

SOURCE: RedChip Companies, Inc.

"We remained focused on advancing the development of our lead program, CID-103," said Dr. Wei-Wu He, Executive Chairman and Principal Executive Officer of CASI. "We dosed the first patient in the Phase 1/2 trial evaluating the safety and tolerability of CID-103 in adult patients with active and chronic active renal allograft antibody-mediated rejection (AMR) in China. We also completed the enrollment of Part A (the dose-escalation part) of our ongoing Phase 1/2 study in immune thrombocytopenia (ITP), with the maximum tested dose of 1,200 mg."

Business Highlights

Program Updates and Upcoming Milestones

• CID-103 for Antibody-Mediated Rejection (AMR) for Renal Allografts

  • Approval of clinical trial application by China NMPA for Phase 1/2 study

  • First patient dosed in Phase 1/2 study in China

• CID-103 for Immune Thrombocytopenia (ITP)

  • Completed enrollment in Part A, the dose-escalation part, of the ongoing Phase 1/2 study, with the maximum tested dose of 1,200 mg

Corporate

• Completed $15 million convertible note financing pursuant to certain convertible note purchase agreement with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He

• Dr. Wei-Wu He, Ph.D., assumed the role of the Company's principal executive officer while continuing to serve as Executive Chairman

• Subsequent to quarter-end, received a favorable final award in the Juventas arbitration, pursuant to which the tribunal rejected all of Juventas's allegations of breach, determined that Juventas had wrongfully terminated the relevant agreements, and awarded the Company amounts totaling well over RMB 100 million

• Entered into a Settlement Agreement with Acrotech Biopharma Inc., pursuant to which the prior purported termination of the EVOMELA^® license and related agreements was rescinded and the agreements remain in full force and effect, subject to certain revisions

• Ordinary shares began to be quoted for trading on the OTCQB market under the ticker CASIF

First Half 2026 Financial Highlights

Revenues for the first half of 2026 were $9.8 million, representing a 5.8% decrease compared to $10.4 million in the same period last year. The decline in revenue was primarily attributable to the product transition from EVOMELA^® to the locally manufactured MAFALAN^®, which remains in its market‑expansion phase.

Cost of revenue for the first half of 2026 was $2.2 million, representing a 53.2% decrease compared to $4.7 million in the same period last year. The decrease was mainly attributable to lower unit cost for MAFALAN^® than that of EVOMELA^®.

Research and development expenses for the first half of 2026 were $2.3 million, representing a 37.8% decrease compared to $3.7 million in the same period last year. The decrease was mainly attributable to decreased clinical studies costs for our pipeline products, as well as decreased labor cost.

General and administrative expenses for the first half of 2026 were $14.3 million, representing a 3.6% increase compared to $13.8 million in the same period last year. The increase was mainly attributable to increased legal fees, partially offset by decreased labor cost.

Selling and marketing expenses for the first half of 2026 were $7.5 million, representing an 18.5% decrease compared to $9.2 million in the same period last year. The decrease was mainly attributable to decreased labor cost and decreased travel and conference fees.

Net loss for the first half of 2026 was $20.0 million, compared to $24.1 million in the same period last year.

As of June 30, 2026, cash and cash equivalents of the Company was $3.8 million, compared to $5.6 million as of December 31, 2025.

As of June 30, 2026, total outstanding shares of the Company were 20,555,873.

Nasdaq Delisting and OTCQB Quotation

On February 23, 2026, the Company received a determination letter from the Hearings Panel of The Nasdaq Stock Market notifying the Company that the Panel had determined to delist the Company's securities due to the Company's failure to satisfy Nasdaq's continued listing requirements. As a result, trading in the Company's securities was suspended at the opening of business on February 26, 2026. On June 23, 2026, Nasdaq filed Form 25 in relation to such delisting decision.

On April 14, 2026, the Company's ordinary shares began to be quoted for trading on the OTCQB market under the ticker CASIF.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical-stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging preclinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. In parallel, CASI is actively recruiting and dosing patients in two ongoing Phase 1/2 studies in immune thrombocytopenia (ITP) and active and chronic active renal allograft antibody-mediated rejection.

More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties related to the going-private proposal made by Dr. Wei-Wu He; uncertainties related to the possibility that the transaction for the divestiture of certain assets in China (the "Transaction") will not occur as planned if events arise that result in the termination of the Equity and Assets Transfer Agreement, or if one or more of the various closing conditions to the Transaction are not satisfied or waived; the possibility that our plan with respect to our business operations after the consummation of the Transaction can be implemented successfully; our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to receive approval for renewal of license of our existing products; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that results in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; uncertainties regarding the timing, enforcement and collection of the amounts awarded to the Company in the Juventas arbitration; risks associated with the Company's obligations under the Settlement Agreement with Acrotech, including applicable minimum purchase obligations; the risk related to the Company's ongoing development of and regulatory application for CID-103 with respect to the treatment of antibody-mediated rejection for organ transplant and the license arrangements of CID-103; risks relating to interests of our largest shareholder and our Chairman that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

EVOMELA^® and FOLOTYN^® are proprietary to Acrotech Biopharma Inc. and its affiliates.

COMPANY CONTACT:

Deanna Qian
+86 6561 8789
deannaq@casi.cn

Financial Table Follows
CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Balance Sheets
(In USD thousands, except share and per share data)

CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)

SOURCE: CASI Pharmaceuticals

Second Quarter 2026 Financial and Operating Highlights

• Funds flow from operations: Increased to $7.13 million from $1.85 million in the prior quarter, primarily driven by a $4.07 million increase in operating netback.

• Net income: Delivered net income of $2.34 million ($0.01 per basic and diluted share), reversing the first quarter 2026 net loss of $2.38 million.

• Capital investments: Deployed $1.52 million in capital expenditures focused on high-impact development initiatives, including the FR-1836 crude oil development well and the Cascadura booster compression project.

• Production: Achieved 4,433 boe/d, representing a 5% decrease from 4,657 boe/d in the first quarter of 2026, primarily due to planned third-party infrastructure maintenance at Atlantic LNG that temporarily constrained natural gas production.

• Petroleum and natural gas sales: Totalled $17.47 million, a 39% increase from $12.54 million in the prior quarter, driven primarily by higher realized pricing across all commodity streams.

• Realized commodity pricing:

• Crude oil and liquids: Averaged $70.13 per barrel, a 19% improvement from $59.02 per barrel in the first quarter of 2026.

• Natural gas: Combined pricing averaged $4.93 per Mcf, up from $3.00 per Mcf in the preceding quarter. Ortoire block realized pricing remained steady at $2.55 per Mcf. Central block realized pricing increased 93% sequentially to approximately $6.56 per Mcf, as June natural gas volumes were redirected to Atlantic LNG Train 2/3 during the Train 4 downtime.

• Operating netback: Generated $24.37 per boe, representing a 77% improvement over the $13.73 per boe recorded in the preceding quarter.

• Net debt and deleveraging: Reduced net debt by 10% sequentially to $68.71 million at quarter-end, supported by $3.55 million in bank debt principal repayments funded through cash flow and financing proceeds.

• Strategic financing and capital structure: Completed a multi-jurisdictional integrated financing in the quarter for net proceeds of $10.20 million, initially comprising an issuance of 26,631,330 common shares and an $8.40 million debenture. Subsequent to quarter-end, the $8.4 million debenture was repaid in full, and the repayment proceeds were redirected to the related subscription by Purebond for 89,765,000 common shares, fully converting the financing into equity and eliminating the debt obligation.

Paul R. Baay, President and Chief Executive Officer, commented:

"Our second quarter financial and operating results demonstrate the strong underlying earning power of our assets when supported by favourable pricing and disciplined execution. Driven by a 77 percent quarterly improvement in operating netback to $24.37 per boe, we generated $7.13 million in funds flow from operations and delivered $2.34 million in net income, successfully reversing our first quarter loss.

Operationally, Touchstone exited the quarter with improved production capacity, enhanced infrastructure, and multiple near-term production optimization opportunities. With the Cascadura booster compressor operating reliably and delivering initial performance ahead of expectations, and several well intervention programs scheduled for the second half of 2026, the Company is well positioned to enhance production as regional pipeline constraints normalize following the planned Atlantic Train 4 outage.

Concurrently, we have taken decisive steps to strengthen our capital structure. Supported by cash flow and financing proceeds, we reduced quarterly net debt by 10 percent, while the post-quarter repayment of our $8.40 million debenture and redirection of proceeds into common shares provides Touchstone with a clearer financial runway to execute our growth strategy."

Second Quarter 2026 Financial and Operational Results Overview

Notes:
(1) Refer to "Advisories - Product Type Disclosures" for further information.
(2) In the table above and elsewhere in this news release, references to "boe" mean barrels of oil equivalent that are calculated using the energy equivalent conversion method. Refer to "Advisories - Oil and Natural Gas Measures" for further information.
(3) Specified or supplementary financial measure. Refer to "Advisories - Non-GAAP and Other Financial Measures" for further information.

Operational Update

Operational execution during the second quarter of 2026 was highlighted by the successful commissioning of the Cascadura booster compressor, the completion and startup of two development crude oil wells on the WD-8 block, and the successful Baraka East 1 ("BRE-1") recompletion on the Central block. While planned third-party infrastructure maintenance at Atlantic LNG temporarily constrained production across the Company's natural gas assets, Touchstone continued to advance key production optimization initiatives and strategic development projects.

Cascadura Area (Ortoire Block)

The Cascadura compressor was commissioned in late June and entered service on July 9, 2026. Following minor post-commissioning troubleshooting and the replacement of a faulty engine oil cooler, the unit is operating reliably and consistently within design expectations. Initial performance has exceeded expectations, with field-estimated gross natural gas production averaging approximately 16.5 MMcf/d, despite the wells remaining choke-restricted while flowing reservoir pressures are gradually reduced.

Natural gas production from the Cascadura and Coho fields during the second quarter was impacted by elevated third-party pipeline pressures associated with the planned 69-day Atlantic LNG Train 4 maintenance outage. Despite these third-party constraints, the Company continued to advance several production optimization initiatives, including the Cascadura-3ST1 workover, the planned Cascadura-5 recompletion, and the planned Cascadura-2ST1 solvent squeeze, all of which are expected to support future production growth.

Central Block

The BRE-1 gas and liquids recompletion was completed in June and exceeded expectations, achieving field- estimated gross production of approximately 2.3 MMcf/d of natural gas and 72 bbls/d of liquids over the first thirty days of operation.

At the Carapal Ridge 3 ("CR-3") well, Touchstone has designed a targeted coiled tubing cleanout and acid stimulation program to combat a localized inflow restriction within the formation. The local service provider has resolved mechanical issues with its coiled tubing unit and is currently function testing. The CR-3 workover is scheduled for execution by late August 2026.

Preparations for the next development well continued during the quarter, including construction of a drilling lease at Baraka.

Atlantic LNG Train 4 underwent planned maintenance from May 26, 2026 through August 3, 2026. During this outage, Touchstone's natural gas volumes from the Central block were redirected to Atlantic LNG Train 2/3, realizing higher LNG pricing due to a structurally higher price formula relative to Train 4.

WD-8 Block

The FR-1835 and FR-1836 development wells were completed and brought onstream in May 2026, performing in line with internal expectations. Production optimization activities are ongoing, including the planned installation of artificial lift on the FR-1836 well, which has been flowing since coming onstream.

Liquidity Update

As at June 30, 2026, the Company reported a working capital deficit of $28.7 million. This figure includes two financing-related current liabilities:

• $10.3 million carrying value of the convertible debenture maturing in August 2028, which is classified as a current liability solely due to the holder's conversion rights; and

• $8.4 million short-term debenture issued during the second quarter of 2026. Subsequent to June 30, 2026, this $8.4 million debenture was repaid with the proceeds redirected into a common share subscription, fully eliminating the liability.

Management continues to proactively execute initiatives to further strengthen Touchstone's financial posture and capital structure. Year-to-date accomplishments include:

• Successfully closing an integrated financing that generated net proceeds of $10.2 million;

• Securing a waiver of the annual debt service coverage ratio covenant under the Company's loan agreement for the year ending December 31, 2026; and

• Expanding operating cash flows supported by stronger realized commodity pricing.

Touchstone has scheduled bank debt principal repayments of approximately $14.2 million over the next 12 months and continues to pursue recovery of approximately $11.1 million in outstanding value added tax ("VAT") receivables.

As detailed in the Company's June 30, 2026 unaudited interim condensed financial statements and accompanying Management's discussion and analysis, management's cash flow projections remain tied to prevailing commodity prices, field production performance, and the timing of capital programs, including certain discretionary development capital. Consequently, the interim financial statements include a note disclosure regarding a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern.

Touchstone remains focused on maintaining operational momentum, optimizing its cost structure, advancing development activities, recovering VAT balances, and working constructively with its existing lenders to ensure appropriate liquidity over the next twelve months and beyond.

Touchstone Exploration Inc.

Touchstone Exploration Inc. is a Calgary, Alberta based company engaged in the business of acquiring interests in petroleum and natural gas rights and the exploration, development, production and sale of petroleum and natural gas. Touchstone is currently active in onshore properties located in the Republic of Trinidad and Tobago. The Company's common shares are traded on the Toronto Stock Exchange and the AIM market of the London Stock Exchange under the symbol "TXP". For further information about Touchstone, please visit our website at www.touchstoneexploration.com or contact:

Paul R. Baay, President and Chief Executive Officer Tel: +1 (403) 750-4487

Scott Budau, Chief Financial Officer

Brian Hollingshead, EVP Engineering and Business Development

Advisories

Working Interest

Touchstone holds a 100 percent working interest in the WD-8 block through a Lease Operatorship Agreement with Heritage Petroleum Company Limited ("Heritage"). In the Cascadura area of the Ortoire block, Touchstone holds an 80 percent working interest, with Heritage holding the remaining 20 percent working interest. On the Central block, Touchstone holds a 65 percent working interest, with Heritage holding the remaining 35 percent working interest.

Forward-looking Statements

The information provided in this news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Such forward-looking statements include, without limitation, forecasts, estimates, expectations, and objectives for future operations that are subject to assumptions, risks, and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expect", "believe", "estimate", "potential", "anticipate", "forecast", "pursue", "aim", "intends" and similar expressions, or are events or conditions that "will", "would", "may", "could" or "should" occur or be achieved. The forward-looking statements contained in this news release speak only as of the date hereof and are expressly qualified by this cautionary statement.

Specifically, this news release includes, but is not limited to, forward-looking statements relating to: the Company's business plans, strategies, priorities and capital development plans; field-estimated production volumes; anticipated developmental drilling activities, including drilling locations, execution timing, and expected production and cash flows therefrom; the anticipated timing of well completion and workover activities, operational startups and production coming online; and Touchstone's current and future financial position, including liquidity, capital structure, and the sufficiency of financial resources to fund near-term debt obligations and future capital expenditures. The Company's actual decisions, activities, results, performance, or achievement could differ materially from those expressed in, or implied by, such forward-looking statements and accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do, what benefits Touchstone will derive from them.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Certain of these risks are set out in more detail in the Company's 2025 Annual Information Form dated March 30, 2026, which is available on the Company's profile on SEDAR+ (www.sedarplus.ca) and on its website (www.touchstoneexploration.com). The forward-looking statements contained in this news release are made as of the date hereof, and except as may be required by applicable securities laws, the Company assumes no obligation or intent to update publicly or revise any forward-looking statements made herein or otherwise, whether as a result of new information, future events or otherwise.

Non-GAAP and Other Financial Measures

This news release references various non-GAAP financial measures, non-GAAP ratios, capital management measures and supplementary financial measures as such terms are defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure. Such measures are not recognized measures under Canadian Generally Accepted Accounting Principles ("GAAP") and do not have a standardized meaning prescribed by IFRS Accounting Standards as issued by the International Accounting Standards Board ("IFRS") and therefore may not be comparable to similar financial measures disclosed by other issuers. Readers are cautioned that the non-GAAP financial measures referred to herein should not be construed as alternatives to, or more meaningful than, measures prescribed by IFRS, and they are not meant to enhance the Company's reported financial performance or position. These are complementary measures that are commonly used in the oil and natural gas industry and by the Company to provide shareholders and potential investors with additional information regarding the Company's performance. Below is a description of the non-GAAP financial measures, non-GAAP ratios, capital management measures and supplementary financial measures disclosed herein.

Operating netback

Touchstone uses operating netback as a key performance indicator of field results. The Company considers operating netback to be a key measure as it demonstrates Touchstone's profitability relative to current commodity prices and assists Management and investors with evaluating operating results on a historical basis. Operating netback is a non-GAAP financial measure calculated by deducting royalty and operating expenses from petroleum and natural gas sales. The most directly comparable financial measure to operating netback disclosed in the Company's consolidated financial statements is petroleum and natural gas revenue net of royalties. Operating netback per boe is a non-GAAP ratio calculated by dividing the operating netback by total production volumes for the period. Presenting operating netback on a per boe basis allows Management to better analyze performance against prior periods on a comparable basis.

Capital expenditures

Capital expenditures is a non-GAAP financial measure that is calculated as the sum of exploration and evaluation asset expenditures and property, plant and equipment expenditures included in the Company's consolidated statements of cash flows and is most directly comparable to cash used in investing activities. Touchstone considers capital expenditures to be a useful measure of its investment in its existing asset base.

Working capital and net debt

Working capital and net debt are capital management measures used by Management to monitor the Company's capital structure to evaluate its true debt and liquidity position and to manage capital and liquidity risk.

Working capital is calculated as current assets minus current liabilities as presented in the applicable consolidated balance sheet, excluding the carrying value of the convertible debenture. Management excludes the carrying value of the convertible debenture from working capital given the instrument has a maturity date in 2028.

Net debt is determined by adding the Company's working capital surplus or deficit to the principal (undiscounted) balance of non-current bank debt and the principal (undiscounted) balance of the convertible debenture. Net debt is most directly comparable to total liabilities as disclosed in the Company's consolidated balance sheets.

Supplementary Financial Measures

Realized commodity price per boe - is comprised of petroleum and natural gas sales as determined in accordance with IFRS, divided by the Company's total production volumes for the period.

Realized crude oil sales per barrel, realized NGL sales per barrel and realized natural gas sales per Mcf - are comprised of sales from the respective product type as determined in accordance with IFRS, divided by the Company's total production volumes of the respective product type for the period. Crude oil sales, NGL sales and natural gas sales are components of petroleum and natural gas sales as disclosed on the consolidated statements of comprehensive income.

Realized crude oil and liquids sales per barrel - is comprised of the sum of crude oil and NGL product sales as determined in accordance with IFRS, divided by the sum of the Company's total crude oil and NGL production volumes for the period. Crude oil and NGL sales are components of petroleum and natural gas sales.

Royalty expense per boe - is comprised of royalty expense as determined in accordance with IFRS, divided by the Company's total production volumes for the period.

For further information, please refer to the "Advisories - Non-GAAP Financial Measures" section of the Company's most recent Management's discussion and analysis for the three and six months ended June 30, 2026 accompanying the June 30, 2026 unaudited interim condensed consolidated financial statements, both of which are available on the Company's profile on SEDAR+ (www.sedarplus.ca) and website (www.touchstoneexploration.com). Touchstone's Management's discussion and analysis is incorporated by reference herein and includes further discussion of the purpose and composition of the specified non-GAAP financial measures consistently used by the Company and detailed reconciliations to the most directly comparable GAAP measures.

Oil and Natural Gas Measures

To provide a single unit of production for analytical purposes, natural gas production has been converted mathematically to barrels of oil equivalent. The Company uses the industry-accepted standard conversion of six thousand cubic feet of natural gas to one barrel of oil (6 Mcf = 1 bbl). The 6:1 boe ratio is based on an energy equivalent conversion method primarily applicable at the burner tip. It does not represent a value equivalency at the wellhead and is not based on either energy content or current prices. While the boe ratio is useful for comparative measures and observing trends, it does not accurately reflect individual product values and may be misleading, particularly if used in isolation, as the value ratio between crude oil and natural gas based on current commodity prices may differ significantly from the 6:1 energy equivalency ratio.

Product Type Disclosures

This news release includes references to crude oil, NGLs, crude oil and liquids, natural gas, and average daily production volumes. Under National Instrument 51-101 - Standards of Disclosure for Oil and Gas Activities ("NI 51-101"), disclosure of production volumes should include segmentation by product type as defined in the instrument. In this news release, references to "crude oil" refer to light and medium crude oil and heavy crude oil; references to "NGLs" refer to condensate and propane; and references to "natural gas" refer to conventional natural gas, all as defined in the instrument. References to "crude oil and liquids" include crude oil and NGLs.

For further information regarding specific product disclosures in accordance with NI 51-101, including second quarter and year-to-date 2026 and 2025 average daily production information by product type, please refer to the "Advisories - Product Type Disclosures" section of the Company's most recent Management's discussion and analysis for the three and six months ended June 30, 2026 accompanying the June 30, 2026 unaudited interim condensed consolidated financial statements, both of which are available on the Company's profile on SEDAR+ (www.sedarplus.ca) and website (www.touchstoneexploration.com).

Abbreviations

The following abbreviations may be referenced in this news release:

bbl(s): barrel(s)
bbls/d: barrels per day
boe: barrels of oil equivalent
boe/d: barrels of oil equivalent per day
Mcf: thousand cubic feet
Mcf/d: thousand cubic feet per day
MMcf: million cubic feet
MMcf/d: million cubic feet per day
MMBtu: million British thermal units
LNG: liquefied natural gas
NGL(s): natural gas liquid(s)

SOURCE: Touchstone Exploration, Inc.